MYC-rearranged mature B-cell lymphomas in children and young adults are molecularly Burkitt Lymphoma.
Journal
Blood cancer journal
ISSN: 2044-5385
Titre abrégé: Blood Cancer J
Pays: United States
ID NLM: 101568469
Informations de publication
Date de publication:
07 Oct 2024
07 Oct 2024
Historique:
received:
24
07
2024
accepted:
23
09
2024
revised:
20
09
2024
medline:
8
10
2024
pubmed:
8
10
2024
entrez:
7
10
2024
Statut:
epublish
Résumé
Aggressive B-cell non-Hodgkin lymphomas (NHL) in children, adolescents, and young adults (CAYA) include Burkitt lymphoma (BL), diffuse large B-cell lymphoma (DLBCL), and a subset of high-grade tumors with features intermediate between these entities whose genetic and molecular profiles have not been completely elucidated. In this study, we have characterized 37 aggressive B-NHL in CAYA, 33 with high-grade morphology, and 4 DLBCL with MYC rearrangement (MYC-R), using targeted next-generation sequencing and the aggressive lymphoma gene expression germinal center B-cell-like (GCB), activated B-cell-like (ABC), and dark zone signatures (DZsig). Twenty-two tumors had MYC-R without BCL2 breaks, and two MYC-non-R cases had BCL6 translocations. MYC-R cases, including DLBCL, carried BL-related mutations and copy number alterations. Conversely, MYC-non-R lymphomas had alterations in the B-cell receptor signaling/NF-κB pathway (71%). DZsig was expressed in 12/13 of MYC-R tumors but only in 2/10 of MYC-non-R GCB tumors (P < 0.001). The 3-year event-free survival (EFS) of the whole cohort was 79.6%. TP53 and KMT2C mutations conferred inferior outcome (3-year EFS P < 0.05). Overall, MYC-R lymphomas in CAYA have a molecular profile similar to BL regardless of their high-grade or DLBCL morphology, whereas MYC-non-R has more heterogeneous genetic alterations closer to that of DLBCL.
Identifiants
pubmed: 39375391
doi: 10.1038/s41408-024-01153-0
pii: 10.1038/s41408-024-01153-0
doi:
Substances chimiques
Proto-Oncogene Proteins c-myc
0
MYC protein, human
0
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
171Subventions
Organisme : Ministry of Economy and Competitiveness | Instituto de Salud Carlos III (Institute of Health Carlos III)
ID : PI18/00471, PI21/00479, MS18/00015
Organisme : Ministry of Economy and Competitiveness | Instituto de Salud Carlos III (Institute of Health Carlos III)
ID : FI22/00063
Organisme : Generalitat de Catalunya (Government of Catalonia)
ID : Investigo 100028TC7
Organisme : Generalitat de Catalunya (Government of Catalonia)
ID : 2021-SGR-01172
Organisme : Generalitat de Catalunya (Government of Catalonia)
ID : ICREA Academia Researcher
Organisme : Government of Catalonia | Departament de Salut, Generalitat de Catalunya
ID : PERIS SL017/20/000204
Organisme : Michael Smith Foundation for Health Research (MSFHR)
ID : Health Professional Investigator Award
Informations de copyright
© 2024. The Author(s).
Références
Swerdlow SH, Campo E, Harris NL, Jaffe ES, Pileri SA, Stein H, et al., editors. WHO classification of tumours of haematopoietic and lymphoid tissues. Revised 4th ed. Lyon: IARC; 2017.
Alaggio R, Amador C, Anagnostopoulos I, Attygalle AD, Araujo IBO, Berti E, et al. The 5th edition of the World Health Organization classification of haematolymphoid tumours: lymphoid neoplasms. Leukemia. 2022;36:1720–48.
doi: 10.1038/s41375-022-01620-2
pubmed: 35732829
pmcid: 9214472
Campo E, Jaffe ES, Cook JR, Quintanilla-Martinez L, Swerdlow SH, Anderson KC, et al. The international consensus classification of mature lymphoid neoplasms: a report from the Clinical Advisory Committee. Blood. 2022;140:1229–53.
doi: 10.1182/blood.2022015851
pubmed: 35653592
pmcid: 9479027
Olszewski AJ, Kurt H, Evens AM. Defining and treating high-grade B-cell lymphoma, NOS. Blood. 2022;140:943–54.
doi: 10.1182/blood.2020008374
pubmed: 34525177
Ok CY, Medeiros LJ. High-grade B-cell lymphoma: a term re-purposed in the revised WHO classification. Pathology. 2020;52:68–77.
doi: 10.1016/j.pathol.2019.09.008
pubmed: 31735344
Perry AM, Crockett D, Dave BJ, Althof P, Winkler L, Smith LM, et al. B-cell lymphoma, unclassifiable, with features intermediate between diffuse large B-cell lymphoma and Burkitt lymphoma: study of 39 cases. Br J Haematol. 2013;162:40–9.
doi: 10.1111/bjh.12343
pubmed: 23600716
Collinge BJ, Hilton LK, Wong J, Ben-Neriah S, Rushton CK, Slack GW, et al. Characterization of the genetic landscape of high-grade B-cell lymphoma, NOS - an LLMPP project. Hematol Oncol. 2021;39:781–4.
Momose S, Weißbach S, Pischimarov J, Nedeva T, Bach E, Rudelius M, et al. The diagnostic gray zone between Burkitt lymphoma and diffuse large B-cell lymphoma is also a gray zone of the mutational spectrum. Leukemia. 2015;29:1789–91.
doi: 10.1038/leu.2015.34
pubmed: 25673238
Sha C, Barrans S, Cucco F, Bentley MA, Care MA, Cummin T, et al. Molecular high-grade B-cell lymphoma: Defining a poor-risk group that requires different approaches to therapy. J Clin Oncol. 2019;37:202–12.
doi: 10.1200/JCO.18.01314
pubmed: 30523719
Ennishi D, Jiang A, Boyle M, Collinge B, Grande BM, Ben-Neriah S, et al. Double-hit gene expression signature defines a distinct subgroup of germinal center B-cell-like diffuse large B-cell lymphoma. J Clin Oncol. 2019;37:190–201.
doi: 10.1200/JCO.18.01583
pubmed: 30523716
Alduaij W, Collinge B, Ben-Neriah S, Jiang A, Hilton LK, Boyle M, et al. Molecular determinants of clinical outcomes in a real-world diffuse large B-cell lymphoma population. Blood. 2023;141:2493–507.
pubmed: 36302166
Chong LC, Ben-Neriah S, Slack GW, Freeman C, Ennishi D, Mottok A, et al. High-resolution architecture and partner genes of MYC rearrangements in lymphoma with DLBCL morphology. Blood Adv. 2018;2:2755–65.
doi: 10.1182/bloodadvances.2018023572
pubmed: 30348671
pmcid: 6199666
Hilton LK, Tang J, Ben-Neriah S, Alcaide M, Jiang A, Grande BM, et al. The double-hit signature identifies double-hit diffuse large B-cell lymphoma with genetic events cryptic to FISH. Blood. 2019;134:1528–32.
doi: 10.1182/blood.2019002600
pubmed: 31527075
pmcid: 6839951
Wagener R, Bens S, Toprak UH, Seufert J, López C, Scholz I, et al. Cryptic insertion of MYC exons 2 and 3 into the immunoglobulin heavy chain locus detected by whole genome sequencing in a case of “MYC-negative” Burkitt lymphoma. Haematologica. 2020;105:e202–5.
doi: 10.3324/haematol.2018.208140
pubmed: 31073073
pmcid: 7109723
King RL, McPhail ED, Meyer RG, Vasmatzis G, Pearce K, Smadbeck JB, et al. False-negative rates for MYC fluorescence in situ hybridization probes in B-cell neoplasms. Haematologica. 2019;104:e248–51.
doi: 10.3324/haematol.2018.207290
pubmed: 30523057
pmcid: 6545835
Love C, Sun Z, Jima D, Li G, Zhang J, Miles R, et al. The genetic landscape of mutations in Burkitt lymphoma. Nat Genet. 2012;44:1321–5.
doi: 10.1038/ng.2468
pubmed: 23143597
pmcid: 3674561
Ramis-Zaldivar JE, Gonzalez-Farré B, Balagué O, Celis V, Nadeu F, Salmerón-Villalobos J, et al. Distinct molecular profile of IRF4-rearranged large B-cell lymphoma. Blood. 2020;135:274–86.
doi: 10.1182/blood.2019002699
pubmed: 31738823
pmcid: 6978155
Schmitz R, Young RM, Ceribelli M, Jhavar S, Xiao W, Zhang M, et al. Burkitt lymphoma pathogenesis and therapeutic targets from structural and functional genomics. Nature. 2012;490:116–20.
doi: 10.1038/nature11378
pubmed: 22885699
pmcid: 3609867
Burkhardt B, Michgehl U, Rohde J, Erdmann T, Berning P, Reutter K, et al. Clinical relevance of molecular characteristics in Burkitt lymphoma differs according to age. Nat Commun. 2022;13:3881.
doi: 10.1038/s41467-022-31355-8
pubmed: 35794096
pmcid: 9259584
Thomas N, Dreval K, Gerhard DS, Hilton LK, Abramson JS, Ambinder RF, et al. Genetic subgroups inform on pathobiology in adult and pediatric Burkitt lymphoma. Blood. 2023;141:904–16.
doi: 10.1182/blood.2022016534
pubmed: 36201743
Swerdlow S, Campo E, Harris N, Jaffe E, Pileri S, Stein H, et al., editors. WHO classification of tumours of haematopoietic and lymphoid tissues. 4th ed. Lyon: IARC; 2008.
Klapper W, Szczepanowski M, Burkhardt B, Berger H, Rosolowski M, Bentink S, et al. Molecular profiling of pediatric mature B-cell lymphoma treated in population-based prospective clinical trials. Blood. 2008;112:1374–81.
doi: 10.1182/blood-2008-01-136465
pubmed: 18509088
Hummel M, Bentink S, Berger H, Klapper W, Wessendorf S, Barth TFE, et al. A biologic definition of burkitt’s lymphoma from transcriptional and genomic profiling. N Engl J Med. 2006;354:2419–30.
doi: 10.1056/NEJMoa055351
pubmed: 16760442
Dave SS, Fu K, Wright GW, Lam LT, Kluin P, Boerma EJ, et al. Molecular diagnosis of Burkitt’s lymphoma. N Engl J Med. 2006;354:2431–42.
doi: 10.1056/NEJMoa055759
pubmed: 16760443
Woessmann W, Zimmermann M, Meinhardt A, Müller S, Hauch H, Knörr F, et al. Progressive or relapsed Burkitt lymphoma or leukemia in children and adolescents after BFM-type first-line therapy. Blood. 2020;135:1124–32.
pubmed: 31961927
Minard-Colin V, Aupérin A, Pillon M, Burke GAA, Barkauskas DA, Wheatley K, et al. Rituximab for high-risk, mature B-cell non-Hodgkin’s lymphoma in children. N Engl J Med. 2020;382:2207–19.
doi: 10.1056/NEJMoa1915315
pubmed: 32492302
pmcid: 7720281
Newman AM, Zaka M, Zhou P, Blain AE, Erhorn A, Barnard A, et al. Genomic abnormalities of TP53 define distinct risk groups of paediatric B-cell non-Hodgkin lymphoma. Leukemia. 2022;36:781–9.
doi: 10.1038/s41375-021-01444-6
pubmed: 34675373
Scholtysik R, Kreuz M, Klapper W, Burkhardt B, Feller AC, Hummel M, et al. Detection of genomic aberrations in molecularly defined Burkitt’s lymphoma by array-based, high resolution, single nucleotide polymorphism analysis. Haematologica. 2010;95:2047–55.
doi: 10.3324/haematol.2010.026831
pubmed: 20823134
pmcid: 2995562
Hans CP, Weisenburger DD, Greiner TC, Gascoyne RD, Delabie J, Ott G, et al. Confirmation of the molecular classification of diffuse large B-cell lymphoma by immunohistochemistry using a tissue microarray. Blood. 2004;103:275–82.
doi: 10.1182/blood-2003-05-1545
pubmed: 14504078
Colomo L, Vazquez I, Papaleo N, Espinet B, Ferrer A, Franco C, et al. LMO2-negative expression predicts the presence of MYC translocations in aggressive B-cell lymphomas. Am J Surg Pathol. 2017;41:877–86.
doi: 10.1097/PAS.0000000000000839
pubmed: 28288039
Vazquez I, Papaleo N, Lop J, Puiggros A, Sanchez-Gonzalez B, Diez-Feijoo R, et al. Lack of expression of LMO2 clone SP51 identifies MYC rearrangements in aggressive large B-cell lymphomas. Virchows Arch. 2021;479:1073–8.
doi: 10.1007/s00428-021-03091-9
pubmed: 33811533
Johnson NA, Slack GW, Savage KJ, Connors JM, Ben-Neriah S, Rogic S, et al. Concurrent expression of MYC and BCL2 in diffuse large B-cell lymphoma treated with rituximab plus cyclophosphamide, doxorubicin, vincristine, and prednisone. J Clin Oncol. 2012;30:3452–9.
doi: 10.1200/JCO.2011.41.0985
pubmed: 22851565
pmcid: 3454768
Sureda-Gómez M, Iaccarino I, De Bolòs A, Meyer MA, Balsas P, Richter J, et al. SOX11 expression is restricted to EBV-negative Burkitt lymphoma and associates with molecular genetic features. Blood. 2024;144:187–200.
doi: 10.1182/blood.2023023242
pubmed: 38620074
Cheung KJ, Rogic S, Ben-Neriah S, Boyle M, Connors JM, Gascoyne RD, et al. SNP analysis of minimally evolved t(14;18)(q32;q21)-positive follicular lymphomas reveals a common copy-neutral loss of heterozygosity pattern. Cytogenet Genome Res. 2012;136:38–43.
doi: 10.1159/000334265
pubmed: 22104078
Wlodarska I, Stul M, De Wolf-Peeters C, Hagemeijer A. Heterogeneity of BCL6 rearrangements in nodular lymphocyte predominant Hodgkin’s lymphoma. Haematologica. 2004;89:965–72.
pubmed: 15339680
Joos S, Falk MH, Lichter P, Haluska FG, Henglein B, Lenoir GM, et al. Variable breakpoints in Burkitt lymphoma cells with chromosomal t(8;14) translocation separate c-myc and the IgH locus up to several hundred kb. Hum Mol Genet. 1992;1:625–32.
doi: 10.1093/hmg/1.8.625
pubmed: 1301171
Hübschmann D, Kleinheinz K, Wagener R, Bernhart SH, López C, Toprak UH, et al. Mutational mechanisms shaping the coding and noncoding genome of germinal center derived B-cell lymphomas. Leukemia. 2021;35:2002–16.
doi: 10.1038/s41375-021-01251-z
pubmed: 33953289
pmcid: 8257491
Grande BM, Gerhard DS, Jiang A, Griner NB, Abramson JS, Alexander TB, et al. Genome-wide discovery of somatic coding and noncoding mutations in pediatric endemic and sporadic Burkitt lymphoma. Blood. 2019;133:1313–24.
doi: 10.1182/blood-2018-09-871418
pubmed: 30617194
pmcid: 6428665
Muppidi JR, Schmitz R, Green JA, Xiao W, Larsen AB, Braun SE, et al. Loss of signalling via Gα13 in germinal centre B-cell-derived lymphoma. Nature. 2014;516:254–8.
doi: 10.1038/nature13765
pubmed: 25274307
pmcid: 4267955
Lenz G, Davis RE, Ngo VN, Lam L, George TC, Wright GW, et al. Oncogenic CARD11 mutations in human diffuse large B cell lymphoma. Science. 2008;319:1676–9.
doi: 10.1126/science.1153629
pubmed: 18323416
Mansouri L, Thorvaldsdottir B, Sutton LA, Karakatsoulis G, Meggendorfer M, Parker H, et al. Different prognostic impact of recurrent gene mutations in chronic lymphocytic leukemia depending on IGHV gene somatic hypermutation status: a study by ERIC in HARMONY. Leukemia. 2023;37:339–47.
doi: 10.1038/s41375-022-01802-y
pubmed: 36566271
Karube K, Enjuanes A, Dlouhy I, Jares P, Martin-Garcia D, Nadeu F, et al. Integrating genomic alterations in diffuse large B-cell lymphoma identifies new relevant pathways and potential therapeutic targets. Leukemia. 2018;32:675–84.
doi: 10.1038/leu.2017.251
pubmed: 28804123
Schmitz R, Wright GW, Huang DW, Johnson CA, Phelan JD, Wang JQ, et al. Genetics and pathogenesis of diffuse large B-cell lymphoma. N Engl J Med. 2018;378:1396–407.
doi: 10.1056/NEJMoa1801445
pubmed: 29641966
pmcid: 6010183
Chapuy B, Stewart C, Dunford AJ, Kim J, Kamburov A, Redd RA, et al. Molecular subtypes of diffuse large B cell lymphoma are associated with distinct pathogenic mechanisms and outcomes. Nat Med. 2018;24:679–90.
doi: 10.1038/s41591-018-0016-8
pubmed: 29713087
pmcid: 6613387
Wright GW, Huang DW, Phelan JD, Coulibaly ZA, Roulland S, Young RM, et al. A probabilistic classification tool for genetic subtypes of diffuse large B cell lymphoma with therapeutic implications. Cancer Cell. 2020;37:551–68.
doi: 10.1016/j.ccell.2020.03.015
pubmed: 32289277
pmcid: 8459709
Klapper W, Kreuz M, Kohler CW, Burkhardt B, Szczepanowski M, Salaverria I, et al. Patient age at diagnosis is associated with the molecular characteristics of diffuse large B-cell lymphoma. Blood. 2012;119:1882–7.
doi: 10.1182/blood-2011-10-388470
pubmed: 22238326
Richter J, John K, Staiger AM, Rosenwald A, Kurz K, Michgehl U, et al. Epstein–Barr virus status of sporadic Burkitt lymphoma is associated with patient age and mutational features. Br J Haematol. 2022;196:681–9.
doi: 10.1111/bjh.17874
pubmed: 34617271
Wästerlid T, Nordström L, Freiburghaus C, Pedersen M, Nørgaard P, Gang AO, et al. Frequency and clinical implications of SOX11 expression in Burkitt lymphoma. Leuk Lymphoma. 2017;58:1760–3.
doi: 10.1080/10428194.2016.1258701
pubmed: 27869516
López C, Kleinheinz K, Aukema SM, Rohde M, Bernhart SH, Hübschmann D, et al. Genomic and transcriptomic changes complement each other in the pathogenesis of sporadic Burkitt lymphoma. Nat Commun. 2019;10:1459.
doi: 10.1038/s41467-019-08578-3
pubmed: 30926794
pmcid: 6440956
Hilton LK, Collinge BJ, Ben-Neriah S, Alduaij W, Shaalan H, Weng A, et al. Motive and opportunity: MYC rearrangements in high-grade B-cell lymphoma with MYC and BCL2 rearrangements-an LLMPP study. Blood. 2024;144:525–540.
López C, Burkhardt B, Chan JKC, Leoncini L, Mbulaiteye SM, Ogwang MD, et al. Burkitt lymphoma. Nat Rev Dis Prim. 2022;8:78.
doi: 10.1038/s41572-022-00404-3
pubmed: 36522349
Szczepanowski M, Lange J, Kohler CW, Masque-Soler N, Zimmermann M, Aukema SM, et al. Cell-of-origin classification by gene expression and MYC-rearrangements in diffuse large B-cell lymphoma of children and adolescents. Br J Haematol. 2017;179:116–9.
doi: 10.1111/bjh.14812
pubmed: 28643426
Salaverria I, Martin-Guerrero I, Wagener R, Kreuz M, Kohler CW, Richter J, et al. A recurrent 11q aberration pattern characterizes a subset of MYC-negative high-grade B-cell lymphomas resembling Burkitt lymphoma. Blood. 2014;123:1187–98.
doi: 10.1182/blood-2013-06-507996
pubmed: 24398325
pmcid: 3931189
Shestakova A, Shao L, Smith LB, Ryan R, Bedell V, Murata-Collins J, et al. High-grade B-cell lymphoma with concurrent MYC rearrangement and 11q aberrations: clinicopathologic, cytogenetic, and molecular characterization of 4 cases. Hum Pathol. 2023;136:34–43.
doi: 10.1016/j.humpath.2023.03.013
pubmed: 36997031
Grygalewicz B, Woroniecka R, Rymkiewicz G, Rygier J, Borkowska K, Kotyl A, et al. The 11q-gain/loss aberration occurs recurrently in MYC-negative Burkitt-like Lymphoma With 11q Aberration, as well as MYC-positive Burkitt lymphoma and MYC-positive high-grade B-cell lymphoma, NOS. Am J Clin Pathol. 2018;149:17–28.
doi: 10.1093/ajcp/aqx139
Havelange V, Ameye G, Théate I, Callet-Bauchu E, Lippert E, Luquet I, et al. The peculiar 11q-gain/loss aberration reported in a subset of MYC-negative high-grade B-cell lymphomas can also occur in a MYC-rearranged lymphoma. Cancer Genet. 2016;209:117–8.
doi: 10.1016/j.cancergen.2015.12.005
pubmed: 26776268
Gonzalez-Farre B, Ramis-Zaldivar JE, Salmeron-Villalobos J, Balagué O, Celis V, Verdu-Amoros J, et al. Burkitt-like lymphoma with 11q aberration: a germinal center-derived lymphoma genetically unrelated to Burkitt lymphoma. Haematologica. 2019;104:1822–9.
doi: 10.3324/haematol.2018.207928
pubmed: 30733272
pmcid: 6717587